Eli Lilly & Co. (LLY) Valuation
Historical valuation analysis based on 1280 data points (2021-09-13 to 2026-10-16)
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardianc...
Eli Lilly & Co. (LLY) currently trades at a P/E ratio of 41.95 (historical range: 30.17–143.46, median: 52.61), placing it at the 22th percentile — below its historical average, P/S ratio of 14.06 (range: 7.38–22.87, 55th percentile — near its historical average), EV/EBITDA of 30.91 (range: 25.72–120.14, 9th percentile).
Eli Lilly & Co. trades below its historical valuation range, with most metrics below their median levels.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 41.95 | 52.61 | 22th | below its historical average |
| P/S Ratio | 14.06 | 13.73 | 55th | near its historical average |
| EV/EBITDA | 30.91 | 49.87 | 9th | cheap relative to its history |
| FCF Yield | 1.62% | 1.05% | 62th | below its historical average |
Eli Lilly & Co. (LLY) Valuation & P/E History
Eli Lilly & Co. (LLY) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry currently trading at $1255.73 with a market capitalization of $1.12 trillion. This page provides historical valuation analysis for LLY based on 1280 data points covering 2021-09-13 to 2026-10-16. The P/E ratio of 41.95 is below the historical median of 52.61, placing LLY at the 22th percentile of its valuation range. The P/S ratio of 14.06 compares to a median of 13.73.
LLY Valuation Metrics & Historical Range
The valuation table above shows Eli Lilly & Co.'s current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether LLY is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests LLY is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Eli Lilly & Co..
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is LLY Overvalued or Undervalued?
Eli Lilly & Co. trades below its historical valuation range, with most metrics below their median levels. The overall valuation percentile of 29 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive LLY is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full LLY analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.LLY trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.